FDA Approves FLUDARABINE PHOSPHATE — Areva Pharmaceuticals
Areva Pharmaceuticals today announced the approval of its Abbreviated New Drug Application (ANDA090724) for fludarabine phosphate injection, a key offering in the IV oncology segment. This approval expands the manufacturer's pipeline while intensifying price competition within the market for established fludarabine therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed